Kura Oncology amended executive employment agreements for Troy E. Wilson, Brian Powl and Kathleen Ford to modify severance provisions.Original SEC Filing: Kura Oncology, Inc. [ KURA ] - 8-K - Jul. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important infor…
The FIT-001 Phase 1a/1b study of darlifarnib plus cabozantinib in advanced RCC demonstrated durable antitumor activity, with ORR of 33–50% and mPFS of 13 months in cabozantinib-naive patients. Safety was manageable, and dose optimization is ongoing for future Phase 3 trials.Original document: Kura…
Durable clinical activity was observed with darlifarnib plus cabozantinib in advanced ccRCC, with response rates up to 50% and a median progression-free survival of 13 months. The combination was well tolerated, and a global Phase 1b study is ongoing to optimize dosing.Original document: Kura Oncol…
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –– Activity compares favorably with historical outcomes for TKI and HIF-2α monotherapies -–– Combination was well tolerated…
